Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The company enters into collaborations with leading next-generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trial
Under the 5-year exclusive agreement, Artemis DNA will provide Datar's pioneering cancer detection Liquid Biopsies in the USA and Vietnam markets
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Subscribe To Our Newsletter & Stay Updated
